Overview
SVRA market data
Price History
SVRA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.43 – $7.01 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.1K · P/B 6.04 · P/S 4,169.48.
Company News
Savara Announces European And Australian Patents Granted Covering MOLBREEVI Liquid Formulation, Securing Protection Through March 2041Benzinga · Jul 30, 2026, 12:11 PM
Savara Announces Chief Financial and Administrative Officer TransitionBenzinga · Jun 8, 2026, 9:15 PM
8-K filing — Savara Inc (SVRA)SEC EDGAR · Jun 8, 2026, 8:15 PM
Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFOBenzinga · Jun 8, 2026, 8:15 PM
Savara Announces Participation in the 2026 Jefferies Global Healthcare ConferenceBenzinga · May 27, 2026, 9:15 PM
Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International ConferenceBenzinga · May 20, 2026, 12:25 PM
Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP At ATS 2026 International ConferenceBenzinga · May 18, 2026, 7:05 PM
Savara Q1 EPS $(0.15) Misses $(0.14) EstimateBenzinga · May 12, 2026, 9:10 PM
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceBenzinga · May 11, 2026, 9:10 PM